Analysts Expect Accuray Incorporated (ARAY) Will Announce Quarterly Sales of $91.29 Million
Equities analysts expect Accuray Incorporated (NASDAQ:ARAY) to post sales of $91.29 million for the current quarter, according to Zacks. Two analysts have issued estimates for Accuray’s earnings, with the lowest sales estimate coming in at $90.58 million and the highest estimate coming in at $92.00 million. Accuray reported sales of $87.50 million during the same quarter last year, which indicates a positive year-over-year growth rate of 4.3%. The company is expected to issue its next quarterly earnings results on Tuesday, January 30th.
According to Zacks, analysts expect that Accuray will report full-year sales of $91.29 million for the current year, with estimates ranging from $397.70 million to $398.53 million. For the next fiscal year, analysts forecast that the firm will post sales of $415.27 million per share, with estimates ranging from $415.03 million to $415.50 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Accuray.
Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The business had revenue of $91.00 million during the quarter, compared to analyst estimates of $88.26 million. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. Accuray’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) EPS.
In other news, CEO Joshua Levine sold 17,093 shares of the stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $4.86, for a total value of $83,071.98. Following the completion of the transaction, the chief executive officer now owns 1,435,428 shares of the company’s stock, valued at approximately $6,976,180.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Kelly Londy sold 99,136 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total value of $420,336.64. The disclosure for this sale can be found here. Insiders sold a total of 125,549 shares of company stock valued at $550,135 in the last three months. Corporate insiders own 3.90% of the company’s stock.
Several large investors have recently made changes to their positions in ARAY. Vident Investment Advisory LLC raised its position in shares of Accuray by 75.4% in the 3rd quarter. Vident Investment Advisory LLC now owns 4,899,643 shares of the medical equipment provider’s stock worth $19,599,000 after acquiring an additional 2,106,215 shares in the last quarter. Neuberger Berman Group LLC raised its position in shares of Accuray by 9.9% in the 3rd quarter. Neuberger Berman Group LLC now owns 5,272,695 shares of the medical equipment provider’s stock worth $21,091,000 after acquiring an additional 473,008 shares in the last quarter. Boston Partners raised its position in shares of Accuray by 22.2% in the 3rd quarter. Boston Partners now owns 2,276,184 shares of the medical equipment provider’s stock worth $9,105,000 after acquiring an additional 414,070 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Accuray by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 6,447,130 shares of the medical equipment provider’s stock worth $30,623,000 after acquiring an additional 286,011 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Accuray by 31.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,124,803 shares of the medical equipment provider’s stock worth $5,343,000 after acquiring an additional 266,790 shares in the last quarter. 78.86% of the stock is owned by hedge funds and other institutional investors.
Accuray (ARAY) opened at $5.25 on Monday. The company has a quick ratio of 0.92, a current ratio of 1.48 and a debt-to-equity ratio of 2.44. Accuray has a 52-week low of $3.60 and a 52-week high of $6.00.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.